Cadwalader, Fried Frank, Gibson Dunn, Morgan Lewis, Sullivan & Cromwell, and leading Irish firms A&L Goodbody and Dillon Eustace are advising on the $6.7 billion cash-and-stock sale of Dublin-based biotechnology company Elan to U.S. generic pharmaceutical firm Perrigo, which will also assume $1.9 billion of the Irish drugmaker's debt. The transaction marks the end of a months-long engagement by corporate and litigation lawyers at Cadwalader on Elan's behalf.
Seven Firms Lead on $8.6 Billion Deal for Drugmaker Elan
The Am Law Daily
July 29, 2013